JW Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of cell immunotherapy products. Since its inception in 2016, the company has established a comprehensive platform for product development in this field, focusing on a diverse pipeline that addresses hematologic malignancies, solid tumors, and autoimmune diseases. Notably, JW Therapeutics has made significant strides in CAR-T cell therapy, exemplified by the RELIANCE Trial, which showcased the successful manufacturing and clinical trial data generation for relmacabtagene autoleucel (relma-cel) in patients with relapsed/refractory large B-cell lymphoma. This trial demonstrated promising response rates and a potentially improved toxicity profile compared to existing CAR-T therapies approved in other regions.

The company is committed to advancing its innovative pipeline, which includes next-generation cellular immunotherapy approaches that aim to enhance the risk-to-benefit ratio for patients. This includes allogeneic strategies and combination therapies that integrate small molecules and novel gene modifications. JW Therapeutics is also focused on expanding its indications for solid tumors, particularly in high-incidence diseases prevalent in China, such as hepatocellular carcinoma and non-small cell lung cancer. With a robust research and development infrastructure, including a dedicated R&D center in Shanghai, JW Therapeutics is positioned to lead the development of cell immunotherapy in China and contribute to the global landscape of cancer treatment.

China

JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.

JW Therapeutics

Company Details